Astrazeneca PLC (NYSE:AZN) saw some unusual options trading activity on Wednesday. Traders purchased 8,259 put options on the company. This represents an increase of 1,510% compared to the typical daily volume of 513 put options.

Shares of Astrazeneca PLC (NYSE:AZN) opened at 33.95 on Monday. Astrazeneca PLC has a 52-week low of $25.55 and a 52-week high of $35.60. The firm has a market cap of $85.96 billion, a P/E ratio of 22.27 and a beta of 0.74. The firm’s 50-day moving average is $30.33 and its 200-day moving average is $31.81.

Astrazeneca PLC (NYSE:AZN) last announced its quarterly earnings results on Thursday, July 27th. The company reported $0.87 EPS for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.46. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The business had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. During the same period in the previous year, the firm earned $0.83 EPS. The business’s quarterly revenue was down 9.9% on a year-over-year basis. Analysts anticipate that Astrazeneca PLC will post $1.90 earnings per share for the current year.

The firm also recently announced a None dividend, which was paid on Monday, September 11th. Stockholders of record on Friday, August 11th were paid a dividend of $0.44 per share. The ex-dividend date was Wednesday, August 9th. This represents a dividend yield of 2.98%. Astrazeneca PLC’s dividend payout ratio (DPR) is presently 44.92%.

A number of brokerages recently weighed in on AZN. Barclays PLC restated an “overweight” rating on shares of Astrazeneca PLC in a report on Monday, July 3rd. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca PLC in a report on Friday. Leerink Swann downgraded shares of Astrazeneca PLC from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $36.00 to $31.00 in a report on Thursday, July 27th. Zacks Investment Research downgraded shares of Astrazeneca PLC from a “strong-buy” rating to a “sell” rating in a report on Monday, July 17th. Finally, BidaskClub downgraded shares of Astrazeneca PLC from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $34.20.

Institutional investors and hedge funds have recently bought and sold shares of the company. Salem Investment Counselors Inc. purchased a new position in shares of Astrazeneca PLC during the first quarter valued at approximately $107,000. Meeder Asset Management Inc. purchased a new position in shares of Astrazeneca PLC during the second quarter valued at approximately $105,000. WFG Advisors LP increased its stake in shares of Astrazeneca PLC by 36.0% during the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock valued at $127,000 after buying an additional 984 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Astrazeneca PLC by 3,782.0% during the first quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock valued at $121,000 after buying an additional 3,782 shares during the period. Finally, Bronfman E.L. Rothschild L.P. increased its stake in shares of Astrazeneca PLC by 71.2% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock valued at $145,000 after buying an additional 1,769 shares during the period. 14.17% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Astrazeneca PLC Sees Unusually Large Options Volume (AZN)” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/09/24/astrazeneca-plc-sees-unusually-large-options-volume-azn.html.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.